Updates are available Correction dated 2020-12-17
Click to view Correction: https://doi.org/10.1038/S41587-020-00792-5
-
Authors
Cohen, Ron http://orcid.org/0000-0002-9152-5114
,
Francois, Cedric
Crowley, John
Hastings, Paul
King, Rachel
Love, Ted W.
Maraganore, John
McMurry-Heath, Michelle
Levin, Jeremy http://orcid.org/0000-0003-4692-4797
-
License Information
Text and Data Mining valid from 2020-11-25
Version of Record valid from 2020-11-25
-
More Information
Article History
First Online: 25 November 2020
Change Date: 17 December 2020
Change Type: Correction
Change Details: A Correction to this paper has been published: https://doi.org/10.1038/s41587-020-00792-5.
Competing interests
: Ron Cohen is president and CEO, Acorda Therapeutics; Cedric Francois is president and CEO, Apellis Pharmaceuticals; John Crowley is chairman and CEO, Amicus Therapeutics; Paul Hastings is president and CEO, Nkarta Therapeutics; Rachel King is CEO, GlycoMimetics; Ted W. Love is president and CEO, Global Blood Therapeutics; John Maraganore is CEO, Alnylam Pharmaceuticals; Michelle McMurry-Heath is president and CEO, Biotechnology Innovation Organization; Jeremy Levin is chairman and CEO, Ovid Therapeutics, and chairman, Biotechnology Innovation Organization. This Correspondence represents solely the individual and personal views of the authors and signatories, and not those of their respective companies.
Free to read: This content has been made available to all.
